A. Amphoux, V. Vialou, E. Drescher, M. Bruss, C. Mannoury-la-cour et al., Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain, Neuropharmacology, vol.50, pp.941-952, 2006.

J. Asaka, T. Terada, M. Okuda, T. Katsura, and K. Inui, Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3, Pharm. Res, vol.23, pp.697-704, 2006.

T. Assari, S. Cox, M. R. Munday, and B. Pearce, Regulation of alpha(1)-adrenoceptorlinked phosphoinositide metabolism in cultured glia: involvement of protein phosphatases and kinases, Cell. Signal, vol.15, pp.403-412, 2003.

N. L. Baganz, R. E. Horton, A. S. Calderon, W. A. Owens, J. L. Munn et al., Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonintransporter-deficient mice, Proc. Natl. Acad. Sci. U. S. A, vol.105, pp.18976-18981, 2008.

Y. Chen, S. Li, C. Brown, S. Cheatham, R. A. Castro et al., Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin, Pharmacogenet. Genomics, vol.19, pp.497-504, 2009.

Y. Cheng and W. H. Prusoff, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol, vol.22, pp.3099-3108, 1973.

G. Ciarimboli and E. Schlatter, Regulation of organic cation transport, Pflugers Arch, vol.449, pp.423-441, 2005.

G. Ciarimboli, H. Koepsell, M. Iordanova, V. Gorboulev, B. Durner et al., Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation, J. Am. Soc. Nephrol, vol.16, pp.1562-1570, 2005.

M. Cui, R. Aras, W. V. Christian, P. M. Rappold, M. Hatwar et al., The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.8043-8048, 2009.

L. C. Daws, Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy, Pharmacol. Ther, vol.121, pp.89-99, 2009.

G. Eisenhofer, R. Mccarty, K. Pacak, H. Russ, and E. Schomig, Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat, Naunyn Schmiedebergs Arch. Pharmacol, vol.354, pp.287-294, 1996.

M. Eltze, H. Konig, B. Ullrich, and T. Grebe, Failure of AH11110A to functionally discriminate between alpha(1)-adrenoceptor subtypes A, B and D or between alpha(1)-and alpha(2)-adrenoceptors, Eur. J. Pharmacol, vol.415, pp.265-276, 2001.

J. M. Fritschy and R. Grzanna, Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? Prog, Brain Res, vol.88, pp.257-268, 1991.

D. Giardina, M. Crucianelli, R. Romanelli, A. Leonardi, E. Poggesi et al., Synthesis and biological profile of the enantiomers of [4-(4-amino-6, 7-dimethoxyquinazolin-2-yl)-cis-octahydroquinoxalin-1-yl]furan-2-ylmethanone (cyclazosin), a potent competitive alpha 1B-adrenoceptor antagonist, J. Med. Chem, vol.39, pp.4602-4607, 1996.

D. Gorbunov, V. Gorboulev, N. Shatskaya, T. Mueller, E. Bamberg et al., High-affinity cation binding to organic cation transporter 1 induces movement of helix 11 and blocks transport after mutations in a modeled interaction domain between two helices, Mol. Pharmacol, vol.73, pp.50-61, 2008.

K. H. Graefe, B. Friedgen, R. Wolfel, F. Bossle, H. Russ et al., 1?-Diisopropyl2, 4?-cyanine (disprocynium24), a potent uptake2 blocker, inhibits the renal excretion of catecholamines, Naunyn Schmiedebergs Arch. Pharmacol, vol.1, pp.115-125, 1997.

D. Grundemann, J. Babin-ebell, F. Martel, N. Ording, A. Schmidt et al., Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells, J. Biol. Chem, vol.272, pp.10408-10413, 1997.

D. Grundemann, B. Schechinger, G. A. Rappold, and E. Schomig, Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter, Nat. Neurosci, vol.1, pp.349-351, 1998.

D. Grundemann, A. C. Koschker, C. Haag, C. Honold, T. Zimmermann et al., Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells, Br. J. Pharmacol, vol.137, pp.910-918, 2002.

R. Grzanna, U. Berger, J. M. Fritschy, and M. Geffard, Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects, J. Histochem. Cytochem, vol.37, pp.1435-1442, 1989.

M. Hayer-zillgen, M. Bruss, and H. Bonisch, Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3, Br. J. Pharmacol, vol.136, pp.829-836, 2002.

H. Hidaka, M. Inagaki, S. Kawamoto, and Y. Sasaki, Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C, Biochemistry, vol.23, pp.5036-5041, 1984.

R. W. Invernizzi and S. Garattini, Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.28, pp.819-827, 2004.

L. L. Iversen, The uptake of catecholamines at high perfusion concentrations in the rat isolated heart: a novel catechol amine uptake process, Br. J. Pharmacol, vol.25, pp.18-33, 1965.

J. W. Jonker, E. Wagenaar, C. A. Mol, M. Buitelaar, H. Koepsell et al., Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene, Mol. Cell. Biol, vol.21, pp.5471-5477, 2001.

J. W. Jonker, E. Wagenaar, S. Van-eijl, and A. H. Schinkel, Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations, Mol. Cell. Biol, vol.23, pp.7902-7908, 2003.

H. Koepsell, K. Lips, and C. Volk, Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications, Pharm. Res, vol.24, pp.1227-1251, 2007.

B. Lei, Y. Zhang, and C. Han, Changes in mRNA expression induced by sustained noradrenaline stimulation are different for alpha1-adrenoceptor subtypes in HEK293 cells, Clin. Exp. Pharmacol. Physiol, vol.29, pp.1084-1090, 2002.

G. A. Lyles and B. A. Callingham, The effect of DSP-4 (N-[2-chloroethyl]-N-ethyl-2bromobenzylamine) on monoamine oxidase activities in tissues of the rat, J. Pharm. Pharmacol, vol.33, pp.632-638, 1981.

W. E. Lyons, J. M. Fritschy, and R. Grzanna, The noradrenergic neurotoxin DSP-4 eliminates the coeruleospinal projection but spares projections of the A5 and A7 groups to the ventral horn of the rat spinal cord, J. Neurosci, vol.9, pp.1481-1489, 1989.

N. Mamiya, J. R. Goldenring, Y. Tsunoda, I. M. Modlin, K. Yasui et al., Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-93, Biochem. Biophys. Res. Commun, vol.195, pp.608-615, 1993.

M. J. Millan, Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application, Pharmacol. Ther, vol.110, pp.135-370, 2006.

M. J. Millan, F. Lejeune, and A. Gobert, Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents, J. Psychopharmacol, vol.14, pp.114-138, 2000.

M. J. Millan, D. Cussac, A. Gobert, F. Lejeune, J. M. Rivet et al., S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole, J. Pharmacol. Exp. Ther, vol.309, pp.903-920, 2004.

G. Minuesa, C. Volk, M. Molina-arcas, V. Gorboulev, I. Erkizia et al., Transport of lamivudine [(?)-beta-L-2?, 3?-dideoxy-3?-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3, J. Pharmacol. Exp. Ther, vol.329, pp.252-261, 2009.

H. Nakayama, K. Kitaichi, Y. Ito, K. Hashimoto, K. Takagi et al., The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats, Brain Res, vol.1184, pp.260-269, 2007.

A. Newman-tancredi, J. P. Nicolas, V. Audinot, S. Gavaudan, L. Verriele et al., Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors, Naunyn Schmiedebergs Arch. Pharmacol, vol.358, pp.197-206, 1998.

T. Olli-lahdesmaki, M. Tiger, M. Vainio, M. Scheinin, and J. Kallio, Ligand-induced alpha2-adrenoceptor endocytosis: relationship to Gi protein activation, Biochem. Biophys. Res. Commun, vol.321, pp.226-233, 2004.

T. M. Ross, M. C. Jetter, M. E. Mcdonnell, R. E. Boyd, C. D. Connelly et al., alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1, 3-dimethyl-6, 7dihydrothianaphthene as a high-affinity ligand for the alpha(2D) adrenergic receptor, J. Med. Chem, vol.43, pp.765-768, 2000.

H. Russ, W. Engel, and E. Schomig, Isocyanines and pseudoisocyanines as a novel class of potent noradrenaline transport inhibitors: synthesis, detection, and biological activity, J. Med. Chem, vol.36, pp.4208-4213, 1993.

H. Russ, B. Friedgen, B. Konigs, C. Schumacher, K. H. Graefe et al., Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyaninetype inhibitors of extraneuronal monoamine transport, Naunyn Schmiedebergs Arch. Pharmacol, vol.354, pp.268-274, 1996.

Y. Shu, M. K. Leabman, B. Feng, L. M. Mangravite, C. C. Huang et al., Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. U. S. A, vol.100, pp.5902-5907, 2003.

I. S. Song, H. J. Shin, and J. G. Shin, Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes, Xenobiotica, vol.38, pp.1252-1262, 2008.

U. Trendelenburg, The extraneuronal uptake and metabolism of catecholamines, Handbook of Experimental Pharmacology, vol.90, pp.279-319, 1988.

V. Vialou, A. Amphoux, R. Zwart, B. Giros, and S. Gautron, Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation, J. Neurosci, vol.24, pp.2846-2851, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-02008093

V. Vialou, L. Balasse, J. Callebert, J. M. Launay, B. Giros et al., Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice, J. Neurochem, vol.106, pp.1471-1482, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-02008107

Z. J. Wang, O. Q. Yin, B. Tomlinson, and M. S. Chow, OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet, Genomics, vol.18, pp.637-645, 2008.

S. E. Wilkinson, P. J. Parker, and J. S. Nixon, Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C, Biochem. J, vol.294, issue.2, pp.335-337, 1993.

R. Zaczek, J. M. Fritschy, S. Culp, E. B. De-souza, and R. Grzanna, Differential effects of DSP-4 on noradrenaline axons in cerebral cortex and hypothalamus may reflect heterogeneity of noradrenaline uptake sites, Brain Res, vol.522, pp.308-314, 1990.

L. Zhang, M. J. Dresser, A. T. Gray, S. C. Yost, S. Terashita et al., Cloning and functional expression of a human liver organic cation transporter, Mol. Pharmacol, vol.51, pp.913-921, 1997.

O. Zolk, T. F. Solbach, J. Konig, and M. F. Fromm, Functional characterization of the human organic cation transporter 2 variant p. 270Ala N Ser, Drug Metab. Dispos, vol.37, pp.1312-1318, 2009.

R. Zwart, S. Verhaagh, M. Buitelaar, C. Popp-snijders, and D. P. Barlow, Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice, Mol. Cell. Biol, vol.21, pp.4188-4196, 2001.